Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer: evidence of diffusion from urine.
Following an IV infusion of 2.0 g/m2 of Etanidazole, the mean tumor concentration 40 min after injection was 126 micrograms/g in bladder cancer and 65 micrograms/g in cervical cancer. The tumor/plasma concentration ratio was 1.88 in bladder and 0.85 in cervical cancer. This high tumor concentration in bladder cancer could be accounted for by diffusion from a highly concentrated urine. This renders bladder cancer a suitable clinical model for testing this sensitizer.
Awwad
H K
HK
Radiotherapy Department, National Cancer Institute, Cairo, Egypt.
el Badawy
S
S
abd el Baki
H
H
Zaghloul
M
M
el Moneim Osman
A
A
Akoush
H
H
Fairchild
K
K
D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000652:urine; D004058:Diffusion; D017341:Etanidazole; D005260:Female; D006801:Humans; D009593:Nitroimidazoles / Q000493:pharmacokinetics* / Q000652:urine; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics* / Q000652:urine; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000652:urine; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000652:urine
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D017341:Etanidazole